Oridion Microstream(R) Technology Chosen by the Bavarian Red Cross for Improved Patient Safety

JERSUSALEM and NEEDHAM, Massachusetts, December 3 - Oridion Systems Ltd.(SIX Swiss Exchange: ORIDN) today announced that the
Bavarian Red Cross has chosen Microcap(R) portable capnographs for its RTW
(Rettungswagen) medical vehicles. The use of capnography can help paramedic
teams to assess the ventilation status of a patient as well as alert them to
issues that affect respiratory status such as displaced endotracheal tubes,
episodes of respiratory depression as well as the status of resuscitative
efforts. Immediate treatment of these developing conditions can improve the
patient's status and limit the danger of further serious complications.

Since 2007, the DIN 1789 Norm and Rules for German Ambulance Vehicles of
the type "RTW" mandated the use of capnometers when transporting emergency
patients. The Bavarian Red Cross has been looking for a standalone capnograph
unit to fulfill the requirements of DIN 1789, as it believed the utility vs.
cost to be better than incorporating capnography into existing Defibrillators
or Respirators. Furthermore a significant graph of the CO2 curve was a
requirement.

The Bavarian Red Cross tested four different competitive units at four
different sites and after a thorough analysis, chose the Oridion Microcap
capnography monitor. Their selection of the Microcap was based on several
criteria including: ease of use, reliability, portability, ruggedness and
stability of the device. Microcap monitors are one of the Oridion family of
portable monitors employing Microstream capnography technology to provide
accurate, continuous monitoring on intubated and non-intubated patients from
neonate to adult patients in hospital and pre-hospital environments,
including emergency transport.

The ability to accurately monitor CO2 levels in a patient's breathing is
vital for ensuring patient safety - especially in emergency transports.
Studies have shown that capnography is an important tool during emergency
applications. It has proven far superior in recognizing displaced
endotracheal tubes when compared to traditional clinical subjective
evaluations[1]. Other studies show that etCO2 levels should be monitored
during CPR (Cardiopulmonary resuscitation) and should be regarded as having
important prognostic value in predicting the outcome of resuscitative
efforts[2].

Capnography is increasingly being used by paramedics worldwide to help in
their assessment and real-time treatment of both intubated and non-intubated
patients in the pre-hospital setting. This is one of the reasons why the
London Ambulance Service and several states in the US have mandated
capnography for intubated patients in Emergency Medical Services
(ambulances).

Gerry Feldman, President of Oridion Capnography, commented that "I am
pleased that the Bavarian Red Cross has recognized the importance of CO2
monitoring and selected the Microcap. Its superior Microstream capnography
provides accurate monitoring and many other benefits, and most importantly
its routine use improves patient safety."

About Oridion

Oridion Systems Ltd. (www.oridion.comwww.oridion.com) is a global
medical device company specializing in patient safety monitoring. The Company
operates through wholly owned subsidiaries in the United States, Europe, and
Israel.

Oridion develops proprietary medical devices and patient interfaces,
based on its patented Microstream(R) technologies, for the enhancement of
patient safety through the monitoring of the carbon dioxide (CO2) in a
patient's breath. These products provide effective, proven airway management
and are used in various clinical environments, including procedural sedation,
pain management, operating rooms, critical care units, post-anesthesia care
units, emergency medical services, transport, alternate care and other
settings where patients' ventilation may be compromised and at risk.

Certain statements made herein that are not historical are
forward-looking. The words "estimate" "project" "intend" "expect" "believe"
and similar expressions are intended to identify forward-looking statements.
These forward-looking statements involve known and unknown risks and
uncertainties. Many factors could cause the actual results, performance or
achievements of the Company to be materially different from any future
results, performance or achievements that may be expressed or implied by such
forward-looking statements, including, among others, our ability to maintain
profits, the market demands for our Capnography products, our ability to
focus our team on the Capnography business, changes in general economic and
business conditions, inability to maintain market acceptance to the Company's
products, inability to timely develop and introduce new technologies,
products and applications, rapid changes in the market for the Company's
products, loss of market share and pressure on prices resulting from
competition, introduction of competing products by other companies, inability
to manage growth and expansion, loss of key OEM partners, inability to
attract and retain qualified personnel, inability to protect the Company's
proprietary technology.

The Company does not assure any obligation to update the forward looking
information contained in this press release.

[1] Silvestri S, Ralls GA, Krauss B, et al. The effectiveness of
out-of-hospital use of continuous end-tidal carbon dioxide monitoring
on the rate of unrecognized misplaced intubation within a regional emergency
medical services system. Ann Emerg Med 45(5):497-503, 2005.

[2] Miran K, Miljenko K, et al. Partial pressure of end-tidal carbon
dioxide successful predicts cardiopulmonary resuscitation in the field: a
prospective observational study, Critical Care 2008, 12:R115
(doi:10.1186/cc7009)

    For further Oridion information please contact

    Alan Adler, Chairman and Chief Executive Officer
    Walter Tabachnik, Chief Financial Officer
    Elena Gerberg, Investor Relations
    e-mail: investor@oridion.com
    website: www.oridion.com
    phone: +972-2-589-9159
    address: Oridion Systems Ltd., P.O. Box 45025, 91450 Jerusalem, Israel

For further Oridion information please contact: Alan Adler, Chairman and Chief Executive Officer, Walter Tabachnik, Chief Financial Officer, Elena Gerberg, Investor Relations, e-mail: investor at oridion.com, phone: +972-2-589-9159, address: Oridion Systems Ltd., P.O. Box 45025, 91450 Jerusalem, Israel